Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gene Vector logo — Pioneering the future of AAV gene therapy for ophthalmic, ne...

Gene Vector

Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.

Founded 2017 Series A Total: $3.16M Biotechnology

General Information

Company Name Gene Vector
Founded Year 2017
Industries Biotechnology
Funding Stage Series A
Social

Get notified when Gene Vector moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Gene Vector

Gene Vector is a biotechnology company that is dedicated to advancing the development of novel adeno-associated virus (AAV) gene therapy drugs. Founded in 2017, the company is at the forefront of pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases. Gene Vector focuses on creating new treatments for a wide range of conditions, including ophthalmic diseases, neuromuscular disorders, and genetic and metabolic diseases. The company recently received a Series A investment on 07 November 2022. The details of the investors involved in the last investment round are not disclosed at this time. Overall, Gene Vector's focus on innovative gene therapy solutions in the field of biotechnology positions it as a promising player in the healthcare industry.

Taxonomy: gene therapy, AAV therapy, ophthalmic diseases, neuromuscular disorders, genetic diseases, metabolic diseases, drug development, innovation, biopharmaceuticals, pharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• - 07 Nov 2022
Seed Round •••••• 5
Investor Investor
•••• •••• 		10 Mar 2022

Gene Vector Alternatives & Competitors

Gene Vector vs
Epigenic Therapeutics
Epigenic Therapeutics China

Pioneering Epigenetic Medicine

Series A
13 employees
Biotechnology
Gene Vector vs
ImStem Biotechnology, Inc
ImStem Biotechnology, Inc United States

Imstem Biotechnology, Inc. is a biotechnology company focusing on developing cell therapeutic produc...

Grant
11 employees
Biotechnology, Health Care
Gene Vector vs
Certa Therapeutics
Certa Therapeutics

Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases

Grant
10 employees
Biotechnology, Health and Wellness

FAQ About Gene Vector

Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.
Gene Vector was founded in 2017.
Gene Vector operates in the following industries: Biotechnology.
Gene Vector has completed 2 funding rounds, raising a total of $3.16M. The latest funding stage is Series A.
Top alternatives and competitors to Gene Vector include Epigenic Therapeutics, ImStem Biotechnology, Inc, Certa Therapeutics, True North Therapeutics, GenSight Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gene Vector and Epigenic Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Gene Vector and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy